text:
Chapter 14
I can't stop the anger that courses through my veins. Every inch of me wants to scream in the heat of battle. Is this my destiny? Why can't I remember. There's an aura within me. It tempts my very being in so many ways. It is seductive, but not irresistable. Damn, it seems that I've been left here for a reason. I can hear the light cry for help. It too is a child born with no memory. These ruins are ancient and yet so familiar. Each step I take echoes in the past.
"Are you the daughter of Jove?" The voice is faint.
I look ahead, but there's nothing in front of me. "Where are you?"
There is a moment when I hear nothing but the silence. I don't even notice the sparks flowing through my fingers until they crackle against the air. What is this energy? The thunder cracks over my head. A storm?
"You are the daughter of Jove, I knew it."
I turn behind me. "Don't be a coward! Face me with dignity!"
The voice is cold, but welcoming. "It is not yet time for us to meet, but when it is, you'll take my hand without hesitation. I've seen both sides of your soul."
I reach for my sword, but stop inches before the hilt. The lightning dances between my fingers. I let it fly without mercy. "Incredible. I can control the storms."
"Still, the storm does not embrace you as its true master."
I smile and move the clouds. "The storms will be my servants. I will lead them to a glorious victory."
"So says the daughter of a forgotten empire."
"You speak in riddles. Who are you?"
Behind me, I can feel the faint presence of another. "I am one of many followers of a forgotten army lain to rest on the dark side of this galaxy. The Jovian empire used to be so strong. We would follow the strength of lightning. Our duty is to conquer."
"Where are you then?"
"You will find us eventually, my Queen, and then there will be true peace."
Just like that, the presence is gone. No words escape me as I step closer and closer to the ruins. A Queen? Is that what I am? No, not yet. Queens understand the needs of people; they are powerful because of the choices they must make. I am not a Queen, not yet, but if something is forgotten then it must be found. This lightning is strange. It is so familiar and yet so distant. I sense its weakness. If I am its master then it will obey me. I will make it strong again so that my enemies will cower at my feet. The storm is resistant, but that will soon change. This, I promise.
The Earth is colder than it has been for generations. Mercury lowers her visor in an attempt to gather information. It doesn't make sense for either Jadeite or Zoicite to leave their Queen's side, especially after her appearance in front of the Princess.
"Anything new?" Mars steps forward with a look of concern on her face. Something is blocking her connection with the sacred fire.
"I don't think so. Looks like we're on our own."
Mars shivers as they continue on. The air around them feels so dead compared to what it was before. Mercury can sense it as well. Both soldiers are wary of their surroundings. This isn't the same city that either of them had come to know.
"It's too quiet."
Mars nods in agreement. "I know, but we can't do anything about it. We have to find those two and-"
"Kill them." Mercury closes her eyes. "I've always tried to do my best to help others. I was going to be a doctor so I could save lives. Even though I know I have to... I don't think I can take their lives."
Mars stops. "We told Saturn that we would. It's out of our hands now. Letting them live would be selfish. One person or the world. We are strong because we have to make that choice."
Mercury carries on. "And it will haunt us forever. Jupiter really was stronger than all of us. She never even hesitated."
"We'll get her back Amy."
She nods and faces her friend. "Will we really? Her eyes were so dark last time we saw her. What if the fate of the world meant losing a friend?"
"It won't come to that."
"I hope you're right."
Venus walks beside Saturn with her chain in her hands. In her past she was a leader, one of the most fearless warriors of the galaxy, but now she rests on uncertainty. In the past, she was the leader of the others, but right now she doesn't feel like she can lead anyone.
Venus looks over to her younger comrade. "Is something wrong Hotaru?"
"You're crying."
She hadn't even noticed the streaks of water that were falling down her face. "It's nothing."
Saturn can see through the lie. "Tears are the truths behind emotion."
Venus wipes them away and continues on as if nothing had happened. "So, how much further?"
The soldier of silence stops in her tracks. Venus looks back with confusion. Saturn closes her eyes and bows her head. "You shouldn't doubt yourself Mina. The others will need you to be your cheery self."
"What are you-"
"A leader is defined by their weaknesses as much as their strengths. You need to stop thinking about Lita. What happens will happen."
"I can't accept that."
"But you will."
Venus steps forward. "I don't want to talk about this."
Saturn sighs and walks to her side. "Then you will only feel worse when the time comes."
The Princess, despite everything that she has gone through stands and leaves the Prince. Her eyes are colder than they have ever been before.
Neptune bows her head. "Should we not at least take him inside somewhere?"
The Princess stops and turns. "No, we can't do anything for him right now. There's no time to waste."
Uranus sighs. "Are you sure about this?"
"Yes." With that word, the Princess leaves with her Outer guard. None of them know where they are going, but they have faith in their princess. Her eyes hide the emotion that she would have readily expressed not a few hours earlier. "We're going to take the battle to Beryl. Michelle, can your mirror show us the way?"
She nods. "I can, but it will take a moment."
Pluto sighs. "We should wait for the others. We will be much stronger together."
The Princess shakes her head. "No, I won't ask that of them. They have their own demons to face."
No one says anything for a moment. Neptune stands with her talisman in front of her. She turns to the others with a sad smile. "We need to go north."
"To where?"
Neptune sighs. "The Tokyo tower."


text:
wikiHow to Read Stock Quotes
Two Methods:Finding Your StockDecoding a Stock QuoteCommunity Q&A
If you've developed an interest in the stock market, you no doubt have a company or two in mind that you'd like to investigate. Every publicly traded company can be looked up and analyzed through their stock quotes. These quotes are snapshots of the company's stock, and how well it is performing on the market. Follow this guide to make sense of the jargon and educate your investment decisions.
Finding Your Stock
1Use a financial web service. There are free and paid websites that will allow you to look at stock quotes. Google, MSN, Yahoo!, and many more offer free stock tracking services.
- Web services will often provide much more detailed information and graphs that aren't provided by newspaper listings.
2Look it up in a newspaper. In order to find your stock in a newspaper, you will need to know the stock symbol. This is a collection of letters that serve as shorthand for the company name. It may be similar to the name, but oftentimes the letters don't correlate.
- Some publications may list the company name along with the symbol.
- You can find the symbol for any publicly traded company by searching for it on a variety of financial websites.
- Company websites often list their stock symbol on the website.
3Check the ticker. Most financial TV programs and channels will have a stock ticker running along the bottom. These provide a brief glimpse at the stock, and usually do not have as much information as either a newspaper or a website.
Decoding a Stock Quote
1Learn all of the terminology. Most every listing will provide you with the same basic information. Listings typically show the following information:
- Close/Current Price – The price at the end of the trading day.
- 52W high/low – This is the range of lowest and highest price of the stock in the last year.
- Div – Dividend paid per share. May be blank.
- % Yield – The percentage of the dividend return compared to stock price.
- EPS – Earnings per share.
- P/E – Price/Earnings ratio. This is the earnings compared to the price of the stock.
- Vol – This is Volume, the number of shares traded on the previous day.
- High/Low – The highest and lowest trading price the previous day.
- Net chg – This is the change from the previous day's closing price.
- Shares – Number of shares held by investors.
- Mkt cap – Total value of the company on the market.
2Make note of the current price. The current price is the price of one share at the close of trading the previous day. This price should only be taken as a guideline, because the price will continue to fluctuate even after the market has closed.
- The price may not have a currency symbol next to it.[1]
3Check the 52-week high and low price. 52-week high and low gives you a historical view of how much the stock has fluctuated. This information can be helpful in determining the general direction of a stock's price.
4Find the dividend, if any. Some stocks pay investors a dividend. A dividend is equity paid directly to the investor. Not every stock pays out a dividend. If the company does not pay a dividend, this section may be blank or occupied by a dash.
- Dividends can be paid monthly, quarterly, semi-annually or annually.
- In some cases, dividends are reinvested; that is, the investor receives additional stock instead of cash when the dividend is paid.
5Calculate the Earnings Per Share (EPS). The EPS is a measure of the current stock price compared to the earnings for the company over the last four fiscal quarters. It is calculated by dividing the net income of the company by the number of outstanding shares.[2]
- EPS is generally considered one of the most important aspects of determining the value of a stock.
6Calculate the Price to Earnings (P/E) ratio. This number is the stock's current price divided by the most recent 12-month earnings amount per share (EPS). The P/E ratio is designed to show you if a stock price is overvalued or undervalued.
- A high P/E ratio means that investors expect that higher earnings in the future. A low P/E means that they expect less.
- Compare P/E ratios to other companies in the same sector to see how well it is performing.
7Check the stock's volume. The volume is the amount of shares that have been traded in the current session (usually the last day). You may also see an average volume, which is the number of shares traded during a specific period. The length of the average varies based on which stock price report service you use.[3]
8Find the High/Low column or Range. This will show you the stock's lowest and highest price of the day. This can help give you a sense of the volatility of a stock.
9See how the stock fared yesterday. The Net Change column will tell you how the stock has performed compared to the day before. If a stock is "up," it's because it traded at a higher value than the day before. Some stock price report services call this measure the open price instead of the closing price.
10Determine the total shares for the stock. This number is sometimes reported as shares and reflects the all shares, purchased and available for purchase, for the stock.
11Look at the market capitalization. This amount, which is generally called the market cap, is the total value of the company on the stock market. To arrive at this number, you multiple the total available shares of stock by the current stock price.
Community Q&A
How much should my overall portfolio composition be devoted to bonds?It's usually recommended that you devote up to 40% of your portfolio to bonds.
Do some stocks require a minimum to purchase?wikiHow ContributorYes, they will usually give you a price that is required for purchase (or an investment quote).
Why do some stockbroker companies have decimals in their stock prices that don't reflect the stock price?wikiHow ContributorSome companies decrease or increase prices based on supply, investment, or if you are investing in housing material stock. It also depends on the need of the demand and need of stock.
Article Info
Categories: Technical Reading
In other languages:
Español: leer cotizaciones de acciones, Português: Entender a Cotação de Ações, Русский: читать котировки, Deutsch: Aktienkurse lesen und verstehen, Italiano: Leggere le Quotazioni delle Azioni, Français: lire des informations boursières, 中文: 查看股票报价, Bahasa Indonesia: Memahami Istilah di Dunia Saham
Thanks to all authors for creating a page that has been read 101,160 times.

subset: commoncrawl


text:
*Does Not Qualify for Free Shipping
Prevail Bariatric Adult Brief, Latex Free (Up to 94")- One pkg of 10 each
- Add Your Review
- Brand: Prevail
Prevail Bariatric Adult Brief Up to 94" Waist, Latex-free
Wide, Soft, Stretch Side Panels for a more secure comfortable fit, dual Refastening Strips for strong closure that will stay in place even under Stress. Offers a full-mat core design, cloth-like backsheet with breathable zones for air circulation, Easy-Lock Fastener, tabs that grip without being sticky and breathable core for moderate to heavy incontinence protection, soft, breathable outer fabric is more comfortable for the wearer and reduces the risk of skin irritation from the traditional plastic backed adult incontinence product.
- ELF reattaching closure tabs securely grip and hold the outer fabric without being sticky.
- ELF will not stick to gloves or skin.
- Will attach anywhere on the outer fabric for easier application and a customized fit
Prevail Bariatric Adult Brief Up to 94" Waist, Latex-free- One pkg of 10 each
Brand: Prevail
Category: Incontinence Products
The Following product has been added to your cart
$ 16.39


text:
The Education Foundation of Niagara provides grants for small school projects in areas where government or budgetary funding is not available.
Maximum funding amount is $1,000 per school per granting cycle.
*Please send attachments by email firstname.lastname@example.com or via courier.
Funding is directed for projects or initiatives that are not eligible for government or budgetary funding in areas of:
All applications must be received by the Foundation by 4:30 p.m. on the application deadline date.
Final report due date is: February 1st for the October Grant
Our vision is a community where every student has access to all of the enriching opportunities school life offers.
Learn more


text:
With the Nova and Nova Plus, Huawei did two things that a lot of people didn't expect. First, the company included Qualcomm's Snapdragon 625 processors instead of its home-grown Kirin chips that power all of its popular smartphones like the Huawei Mate S, Mate 8, the P9 and P9 Plus, Honor 5X and the just-launched Honor 8.
Huawei Nova
Secondly, Huawei has, probably for the first time, priced the Nova and Nova Plus phones more than what they are probably worth. The Nova is priced at €399 in the mainland which is the same as the 5.2-inch Honor 8. but doesn't really match up to the latter given that the Honor 8 features P9's much-acclaimed Dual Camera setup, a larger display and a Kirin 950 processor which compares more with the Snapdragon 810 chip than the Snapdragon 625 which powers the Nova. In terms of pricing and specifications, the Nova and Nova Plus phones may compete effectively with Samsung's Galaxy A-series phones which aren't as premium as Galaxy S-series phones but offer decent features and specifications to buyers at comparatively lower price points.
Huawei Nova also comes in 'rose gold' #IFA2016 pic.twitter.com/bVnmDZH3Ot— Mobile Choice (@Mobile_Choice) September 1, 2016
Huawei Nova also comes in 'rose gold' #IFA2016 pic.twitter.com/bVnmDZH3Ot
Specifications-wise, Huawei Nova features a 5-inch Full HD display, a decent 3,020 mAh battery with Smart Power 4.0 battery saving technology, a Snapdragon 625 processor, 32GB of on-board storage, a 3D fingerprint sensor, 3GB of RAM and 12-MP and 8-MP cameras. The rear camera features 1.25um larger pixels and an imaging sensor to let you capture better pictures in low light as well as fast autofocus to let you take the right shots at the right time. The 8-MP front camera comes with features like Beauty Makeup 2.0 and Beautiful Skin 3.0 applications to let you make your selfies look better once you're done clicking.
Huawei Nova Plus
Huawei's Nova will cost €399 in Europe and will be available to purchase in Prestige Gold, Mystic Silver and Titanium Grey colour options from October. The larger 5.5-inch Nova Plus will cost €429 and will be available in similar colour options around the same time.
Among the list of upgrades that Nova Plus features over the Nova are a larger display, a more powerful 3,340 mAh battery and a 16-MP rear camera which captures more light to deliver clearer shots even in low light. Both phones will be available in single storage variants of 32GB but looks-wise, the Nova's rear camera is placed right above the fingerprint sensor whereas the rear of the Nova Plus looks exactly like the Nexus 6P which featured a horizontal glass casing shielding the single rear camera lens and Dual LED flash buttons.


text:
We recommend using a modern web browser such as Google Chrome or Microsoft Edge with their default settings.
At the yearly gathering of booklovers held in Chicago's McCormick Place convention center June 22 – 27, Wordsworth the Better World Bookmobile is...
James R. Gaines
Hello, I'm an eBook!
ATTENTION: This item is an eBook. It can be read on iOS, Android, MAC and PC's with a supported eReader. It is not a physical book. eBooks are available via download immediately after you've checked out.
Used Very Good
Shipped from other seller
Ships directly from Better World Books
"Gentlemen," he said, "old Bach is here." Those who heard him said there was "a kind of agitation" in his voice.
So begins James R. Gaines's Evening in the Palace of Reason, setting up what seems to be the ultimate mismatch: a young, glamorously triumphant warrior-king, heralded by Voltaire as the very It Boy of the Enlightenment, pitted against a devout, bad-tempered composer of "outdated" music, a scorned genius in his last years, symbol of a bygone world. The sparks from their brief conflict illuminate a pivotal moment in history.
Behind the pomp and flash, Prussia's Frederick the Great was a tormented man. His father, Frederick William I, was most likely mad; he had been known to chase frightened subjects down the street, brandishing a cane and roaring, "Love me, scum " Frederick adored playing his flute as much as his father despised him for it, and he was beaten mercilessly for this and other perceived flaws. After an unsuccessful attempt to escape, Frederick was forced to watch as his best friend and coconspirator was brutally executed.
Twenty years later, Frederick's personality having congealed into a love of war and a taste for manhandling the great and near-great, he worked hard and long to draw "old Bach" into his celebrity menagerie. He was aided by the composer's own son, C. P. E. Bach, chief keyboardist in the king's private chamber music group. The king had prepared a cruel practical joke for his honoredguest, asking him to improvise a six-part fugue on a theme so fiendishly difficult some believe only Bach's son could have devised it. Bach left the court fuming. In a fever of composition, he used the coded, alchemical language of counterpoint to write A Musical Offering in response. A stirring declaration of everything Bach had stood for all his life, it represented "as stark a rebuke of his beliefs and worldview as an absolute monarch has ever received." It is also one of the great works of art in the history of music.
Set at the tipping point between the ancient and the modern world, the triumphant story of Bach's victory expands to take in the tumult of the eighteenth century: the legacy of the Reformation, wars and conquest, and the birth of the Enlightenment. Most important, it tells the story of that historic moment when Belief -- the quintessentially human conviction that behind mundane appearances lies something mysterious and awesome -- came face to face with the cold certainty of Reason. Brimming with originality and wit, Evening in the Palace of Reason is history of the best kind, intimate in scale and broad in its vision.
Our best deal on used books 3 for $10 and just $3 each additional book. Shop and Save
Shop our Summer Sale going on now.Get discount code »
We match every book you purchase with a book donation. Learn more »
Come save on used books in the Clearance Aisle. Learn more »
All used inventory that ships from Better World Books may come from separate Better World Books distribution centers.
© Better World Books (BetterWorldBooks.com)
- All Rights Reserved Deals | Terms of Use | Privacy Policy | Copyright | Legal


text:
Just thought of a better analogy, I think.
In WWII the Nazis intentionally killed millions of children in their camps and elsewhere.
Meanwhile the Allies killed hundreds of thousands, possibly a million or more, in bombing attacks on nuclear and conventional German and Japanese cities and otherwise. Now I happen to think many of these attacks were not fully justified morally, but I hope you will agree there is a difference in the degree of moral culpability.
That should of course be "nuclear and conventional bombing attacks."


text:
Lawyers for James Hird have declared a drugs saga now into its 21st month "must start again", arguing they have compelling reasons why they should win a court appeal.
Hird's one-day appeal against Justice John Middleton's decision will be held before the full Federal Court on Monday.
Justice Middleton had ruled against Hird and Essendon in September when he confirmed the investigation by the AFL and the Australian Sports Anti-Doping Authority last year into Essendon's peptides program was lawful, and the show-cause notices issued to 34 current and former Bombers would stand.
While Essendon has opted to not appeal, Hird and lawyers Peter Hanks QC, Nicholas Harrington and Rachel Walsh maintain ASADA, an independent body, worked outside of its powers.
A flurry of documents submitted by lawyers for Hird and ASADA were released on Friday, with the Hird camp clearly expressing what it feels should happen next.
"The proper analysis of the present matter is this: the court rules the joint investigation a nullity or ultra vires (beyond powers); the notices are invalid; a permanent injunction in respect of the investigation information issues; ASADA thus has insufficient information of a possible anti-doping rule violation; ASADA can investigate the possible ADRV (Anti-Doping Rule Violations) allegations lawfully; it must start again," Hird's lawyers argue.
ASADA has declared if it was forced to start the probe again, it could compel the AFL to re-issue crucial information gathered during the interview process conducted with both parties in the room, thus nullifying any reason to scrap the show-cause notices. These were re-issued last month.
ASADA, with chief Ben McDevitt overseas, would not comment on Friday when asked if the Anti-Doping Rule Violation Panel had begun assessing the cases brought by ASADA and the players. The players had called for this stage to be fast-tracked, sparking a rebuke from McDevitt.
While the show-cause process continues regardless of the appeal, should ASADA ultimately lose, Hird's lawyers argue "the AFL lacked (and still lacks) power to conduct a post-referral investigation into a possible ADRV".
In its submission, ASADA has declared it has presented "very powerful considerations" against a permanent injunction, endorsing several of Middleton's rulings. The anti-doping body argues Hird has attempted to dismiss factual findings.
"The trial judge found that ASADA and the AFL conducted separate investigations, in the course of which they co-operated with one another, resulting in each making separate and distinct decisions within their own complementary areas of responsibility," ASADA lawyers Tom Howe QC, Sue McNicol QC and Dan Star argue.
ASADA had already argued its investigation was for anti-doping purposes, while the AFL's was for potential governance breaches, of which it ruled on in August last year when Hird, among other penalties to officials and the club, was suspended for 12 months.
Hird had argued in the three-day trial before Justice Middleton that he and the 34 players were not given the right to silence, which they would have had had the AFL not been involved.
"The trial judge found that ASADA did not purport to exert any coercive power and accordingly it did not interfere with any basic rights otherwise available to the players and the appellant," ASADA says in its submission.
"The trial judge found that ASADA did not compel attendance at, and answers to, ASADA's questioning. The exertion of authority was by the AFL, not ASADA. ASADA simply obtained a benefit from use by the AFL of its own powers.
"As noted by the trial judge, there was no suggestion that Mr Hird or any of the players did not understand the legal framework surrounding the interviews – a framework which was based on them agreeing with the AFL to give up rights (in favour of the AFL) in return for the right or privilege of participating in the AFL competition."
In ASADA's notice of contention, its lawyers also point out that Hird's appeal "cuts across" a bid by the 34 players to have their cases expedited.
"If the interests of the 34 players are relevant, so too are the interests of the AFL and the public at large," ASADA says.
"Those interests militate strongly against permanent injunctive relief and favour non-interference with the show-cause notices – particularly since they have re-issued. The evidence since judgment is that, apart from the appellant, all stakeholders favour a full and expeditious consideration of possible ADRVs 'on the merits'."
ASADA maintains the AFL would be compelled to hand over evidence and transcripts should Hird win on appeal.
"Because the AFL retains a post-referral investigative power, the AFL could re-exercise its contractual powers, and re-provide the same information to ASADA. And even if it did not do so, ASADA could exercise newly conferred coercive powers to compel production of the interview transcripts (from the AFL, Essendon and/or interviewees)," ASADA says.
"Those are very powerful considerations against the grant of a permanent injunction."
Hird's lawyers argue the "nature of the illegality cannot be ignored".
The one-day appeal hearing before Justices Susan Kenny, Tony Besanko and Richard White begins at 10.15am.


text:
I am a full time human who loves to eat, drink and explore. Did I mention how much I love the aroma of grilled red pepper?
Member since October 13, 2013
Get the recipes and features that have us talking, plus first dibs on events and limited-batch products.
(Oh, and $10 off your order of $50 or more in the Food52 Shop, too.)


text:
Come and see this beautiful 3.8 acre wooded lot on Arbutus Lake. This spacious lot is loaded with deer and other wildlife along with both mixed hardwoods and conifers. This property has varying elevation and features many possible building sites. Priced at $12,000.00 below the assessed value so if you are looking to build that great Northwoods home or hunting cabin this is your spot.
Features Land
|Waterfront: Y
|Acreage: 1-5 Acres
|Municipality: Nashville, Town Of
|Body of Water:


text:
I am grumpy, enthusiastic, and overanalytical
Films: I don't really do films as such but Shaolin Soccer recently reduced me to a giggling mess.
Music: micro/electrohouse, old arty indie nonsense, post-metal, mainstream pop, folk. Superpitcher/Throwing Muses/Isis/Rachel Stevens/Steeleye Span.
Foods: cheese, whisky, proper beer, lentils, really good white crusty bread, pork pies, curry, cake, Tunnocks Caramel Wafers.


text:
Loddstone Studios was a film production company set up in the 1920s by Eli Marrion's grandfather. It was initially supposed to be named Lode Stone but a mistake by lawyers resulted in it being dubbed incorrectly. It cost ten thousand dollars to set up.
The studio became one of the pillars of the Hollywood industry and made countless stars, but also took advantage of naive individuals such as Ernest Vail, who was tricked into selling the rights to his book for a pittance.
In the 1990s, under Eli Marrion, the studio began to embark on an epic production named Messalina, written by Claudia De Lena. However, the production began to suffer when lead actress Athena Aquitane continually backed out of shooting due to the intimidating behaviour of her ex-husband, Boz Skannet. The film was completed after Cross De Lena, Claudia's brother, eliminated Skannet in return for five percent of the profits and Athena returned to the set.
Soon after this, Eli Marrion fell ill and died of a heart attack.


text:
The display and use of drug information on this site is subject to express terms of use. By continuing to view the drug information, you agree to abide by such terms of use.
GENERIC NAME: CHORIOGONADOTROPIN ALFA - INJECTION (kor-ee-oh-go-NAD-oh-trow-pin alfa)
BRAND NAME(S): Ovidrel
Medication Uses | How To Use | Side Effects | Precautions | Drug Interactions | Overdose | Notes | Missed Dose | Storage
USES: This medication is used to treat certain fertility problems in women. It is the hormone (hCG) that causes the growth and release of a mature egg (ovulation). This medication is usually used in combination with another hormone (FSH) that helps cause healthy ovaries to produce eggs.This medication is not recommended for women whose ovaries no longer make eggs properly (primary ovarian failure).
HOW TO USE: This medicine comes with a Patient Information Leaflet. Read it carefully. Ask your doctor, nurse, or pharmacist any questions that you may have about this medicine.Learn all the preparation and usage instructions in the product package. If any of the information is unclear, consult your health care professional.After injecting the mixing liquid into the vial, gently roll the vial to mix the drug. Do not shake the liquid. Doing so may make this medicine less effective. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid.Wash your hands with soap and water before using this medication. Before injecting the dose, clean the injection site with rubbing alcohol.Inject this medication under the skin, usually the day after your last dose of follicle stimulating medicine (e.g., menotropins) or as directed by your doctor. Dosage is based on your medical condition and response to treatment. Your doctor will do lab/medical tests (e.g., estrogen blood levels, ultrasound) to decide when it is time to use this medication.Be sure to keep all medical appointments so your doctor can closely monitor your response and determine the time you should use this medication.Learn how to store and discard needles and medical supplies safely. Consult your pharmacist for more information.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.


text: At Tue, 7 May 2013 16:55:06 +0200, Stefan Majer wrote: > > after adding a proper setting with the maven-compiler-plugin i get: > > [ERROR] COMPILATION ERROR : > [INFO] ------------------------------------------------------------- > [ERROR] /home/stefan/dev/libvirt-java/src/main/java/org/libvirt/Library.java:[41,28] > cannot find symbol > symbol: method nativeValue(com.sun.jna.Pointer) > location: class com.sun.jna.Pointer > [ERROR] /home/stefan/dev/libvirt-java/src/main/java/org/libvirt/Library.java:[42,16] > cannot find symbol > symbol: method nativeValue(com.sun.jna.Pointer,long) > location: class com.sun.jna.Pointer > > This is because jna version 3.0.9 is specified but this version does > not have these signatures. Yes, JNA 3.3.0 is required as a minimum by libvirt-java. So, as it is now, publishing a new version of libvirt-java to maven would not work / produce a non working artifact because actually a newer JNA would be needed by the code base. Since building is done using a different tool than for publishing, it never turned up to be a problem. (This would probably be another good reason to use a single build tool only, not some awkward combination thereof.) > To make a long story short i would like to propose the following patches: > > 1. remove the ant components (build.xml, build.properties) altogether > and use maven exclusively. You should also remove findbugs.xml then (using the maven findbugs plugin instead). > 2. rename pom.xml.in into pom.xml and specify java source and jna OK, which version of JNA do we use? 3.3.0 to begin with? > 3. remove libvirt-java.spec.in and create the libvirt-java.rpm with > the rpm-maven-plugin. I have no idea / experience about this one. We'll have to see whether this works out for the different distros I think. What about the Debian package build? > 4. update the README and INSTALL accordingly The README should be generated / updated with the correct version number when publishing a source tarball. Apropos publishing: I suppose maven has some kind of scp plugin to copy the different artifacts to the server just like the ant targets "maven", "publish_source", "publish_srpm"? > As result there will be only one file which is responsible for the > build left (pom.xml). > If there is a consensus i will post the patches as a followup. > > Any objections, suggestions ? +1 for doing the transition from (ant+maven) -> maven. -- AV-Test GmbH, Henricistraße 20, 04155 Leipzig, Germany Phone: +49 341 265 310 19 Web:<http://www.av-test.org> Eingetragen am / Registered at: Amtsgericht Stendal (HRB 114076) Geschaeftsfuehrer (CEO): Andreas Marx, Guido Habicht, Maik Morgenstern


text:
The 2016-17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
By Adam J. Fein, Ph.D.
(downloadable PDF file; Released September 2016.)
Corporate License + PowerPoint file with Exhibits: $6,975 BUY NOW
(Allows for use of the report by an unlimited number of employees within the same organization or enterprise worldwide. Includes an additional PowerPoint file with all 102 exhibits that are included in the report.View License Terms.)
Corporate License: $5,950 BUY NOW
(Allows for use of the report by an unlimited number of employees within the same organization or enterprise worldwide. View License Terms.)
Department/Team License: $2,190 BUY NOW
(Allows for use of the report by up to 10 employees within the same organization or enterprise. View License Terms.)
Single-User License: $665 BUY NOW
(Allows for use of the report by one individual person. View License Terms.)
Payment can be made with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal.Contact us if you would like to pay by check. License terms, purchaser's name/email, and a unique transaction ID will be added to the secure PDF file upon checkout. All sales are final after download. Please contact us if you would like to upgrade the license. You will pay only the difference in license fee.
In 2016, pharmaceutical wholesalers face a challenging business environment. The 2016–17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our seventh edition—will help you understand this turbulent environment. It remains the most comprehensive tool for analyzing the economic and business realities of U.S. pharmaceutical distribution. Click here to download a free overview of the 2016-17 report.
The report is researched and written by Adam. J. Fein, Ph.D., one of the world's leading experts on the industry and the author of the influential Drug Channels website. Dr. Fein has synthesized a wealth of statistical data (including more than 100 data-packed exhibits), research studies, financial information, and his own unique business consulting experience into a definitive, nonpartisan resource.
That's what makes this report essential reading for pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, buyers, benefit managers, managed care executives, healthcare policy analysts, investors, consultants—anyone who wants to understand and benefit from this ever-changing industry.
This year's report has been updated, revised, and expanded. This 2016-17 edition contains the latest financial data and market positions of the largest public companies: AmerisourceBergen, Cardinal Health, and McKesson. It updates our analysis of each wholesaler's business segments and underlying business profitability, based upon our proprietary economic models. This information allows you to assess differences among the public wholesalers' business organizations, strategies, and financial performance.
No other report on the market today offers the depth, insight and analysis of the 2016–17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.
Please note that purchase of the 2016–17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors indicates agreement with the terms and conditions of the End User License Agreement. License terms, purchaser's name/email, and a unique transaction ID will be added to the secure PDF file upon checkout. You must purchase a Department/Team or Corporate License if you want to share the report with other people in your company. Upon request, we will refund duplicate purchases of a Corporate License from the same organization.
Pembroke Consulting, Inc., grants to Purchaser, and Purchaser hereby accepts, a limited, terminable, revocable, nontransferable, nonexclusive, nonsublicenseable license to access and use the 2016–17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors only in accordance with the End User License Agreement. License terms, purchaser's name/email, and a unique transaction ID will be added to the secure PDF file upon checkout. We offer three License Options:
- Single User License: This license allows for use of this report by one individual person. This person may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons. Unless a Department/Team License is purchased, a Single User License must be purchased for every person who wishes to use the report within the same organization or enterprise. Buyers who infringe upon these license terms are liable for a Department/Team or Corporate License fee.
- Department/Team License: This license allows for use of this report by up to 10 (ten) employees within the same organization or enterprise. Each of these employees may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons unless a Corporate License is purchased. Buyers who infringe upon these license terms are liable for a Corporate License fee.
- Corporate License: This license allows for use of the report by an unlimited number of employees within the same organization or enterprise worldwide. Each of the employees within this organization or enterprise may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons outside the enterprise or organization.
The 2016–17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors is protected by copyright law. Unauthorized reproduction or distribution of this report, or any portion of it, may result in severe civil and criminal penalties, and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in this license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.
Introduction and Guide to This Report
Chapter 1: Industry Overview
- 1.1. Defining Drug Wholesaling
- 1.1.1. The Products That Wholesalers Sell
- 1.1.2. Full-Line Wholesaling
- 1.1.3. Specialty Distribution
- 1.1.4. Regulation and Supply Chain Security
- 1.2. Overview of Wholesalers' Channel Role
- 1.2.1. Physical Distribution
- 1.2.2. Financial Intermediation
- 1.2.3. Impact on Pharmacy and Provider Reimbursement
- 1.3. Industry Participants
- 1.3.1. Big Three Wholesalers: Revenues and Growth Trends
- 1.3.2. Other Wholesale Market Participants
- 1.3.3. Specialty Product Distribution Market Share
Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies
- 2.1. The Pharmacy Market
- 2.1.1. Outpatient Dispensing Formats
- 2.1.2. Differences Among Outpatient Dispensing Formats
- 2.1.3. Pharmacy Market Size and Structure
- 2.1.4. Recent Changes in Pharmacy Market Structure
- 2.1.5. Wholesale Suppliers to Largest U.S. Pharmacies
- 2.2. Independent Pharmacies
- 2.2.1. Industry Position and Wholesaler Market Shares
- 2.2.2. Wholesaler Services for Independent Pharmacies
- 2.2.3. PSAOs and the Wholesalers' Role in the Pharmacy-Payer Relationship
- 2.2.4. Wholesaler Relationships with Pharmacy Buying Groups
- 2.2.5. Wholesaler Generic Source Programs for Smaller Pharmacies
- 2.3. Retail Chains
- 2.3.1. Brand Distribution Relationships Between Wholesalers and Retail Chains
- 2.3.2. Generic Sourcing Relationships Between Wholesalers and Large Pharmacies
- 2.4 Specialty Pharmacies
- 2.4.1. Specialty Pharmacy Market Participants
- 2.4.2. Wholesalers' Specialty Pharmacies
- 2.4.3. Wholesalers' Role in Manufacturer-Defined Limited Specialty Networks
Chapter 3: Channel Role for Physician Offices/Clinics and Hospitals
- 3.1. The Provider-Administered Drug Market
- 3.1.1. Spending and Sites of Care
- 3.1.2. The Buy-and-Bill System
- 3.1.3. Provider Reimbursement in Buy-and-Bill System
- 3.1.4. Group Purchasing Organizations (GPOs)
- 3.1.5. Contract Management and Chargebacks
- 3.2. Physician Offices
- 3.2.1. Distributors' Services for Physician Offices
- 3.2.2. GPOs for Physician Practices
- 3.2.3. Physician Dispensing
- 3.3. Hospitals
- 3.3.1. Wholesalers' Services for Hospitals
- 3.3.2. Hospital GPOs
- 3.3.3. Specialty Pharmacies at Hospitals and Health Systems
- 3.3.4. Wholesalers and the 340B Drug Pricing Program
Chapter 4: Wholesaler Profitability
- 4.1. Sources of Wholesaler Profits
- 4.1.1. Gross Profit and Gross Margin
- 4.1.2. Operating Profit and Operating Margin
- 4.2. Components of Buy-Side Gross Margin
- 4.2.1. Distribution Service Agreements
- 4.2.2. Specialty Distribution Service Agreements
- 4.2.3. Prompt Payment Discounts
- 4.2.3. Generic Sourcing Formularies
- 4.3. Sell-Side Margins
- 4.3.1. Cost-Minus Discounts
- 4.3.2. Sell-Side Margin Trends for Specialty Drugs
- 4.4. Estimates of Overall Buy-Side and Sell-Side Gross Margins
- 4.5. Gross Profits of Brand vs. Generic Drugs
- 4.5.1. Lifecycle Profits for Traditional Generic Drugs
- 4.5.2. Lifecycle Profits for Provider-Administered Generic Drugs
- 4.5.3. Private Label Generic Drugs
- 4.6. The Profit Impact of Drug Price Inflation
- 4.6.1. Brand-Name Drugs
- 4.6.2. Inventory Appreciation and Revaluation
- 4.6.3. Generic Drugs
- 4.7. Operating Profit
Chapter 5: Financial Stability and Cash Management
- 5.1. Debt, Coverage, and Liquidity Ratios
- 5.2. Balance Sheet Assets
- 5.3. Cash Conversion Cycle
- 5.3.1. Inventory Levels and Days Inventory Outstanding
- 5.3.2. Accounts Receivable and Days Sales Outstanding
- 5.3.3. Accounts Payable and Days Payable Outstanding
- 5.4. Uses of Cash
- 5.5. Return on Invested Capital
- 5.6. Stock Market Performance
Chapter 6: Forces of Change for Drug Distribution
- 6.1. General Trends
- 6.1.1. Growth in U.S. Pharmaceutical Spending
- 6.1.2. Wholesaler Compensation and the ACA's Bona Fide Service Fees
- 6.1.3. The Challenge of Gross-to-Net Pricing
- 6.2. Retail, Mail, and Specialty Pharmacies
- 6.2.1. Competitive Pressure in the Pharmacy Industry
- 6.2.2. The Risks and Rewards of Consolidation and Market Share Concentration
- 6.2.3. Profit Challenges from Payer-Defined Narrow Pharmacy Networks
- 6.2.4. The Outlook for Pharmacy-Dispensed Biosimilars
- 6.3. Physician Offices and Hospitals
- 6.3.1. Hospital Acquisition of Physician Practices and Shifting Sites of Drug Administration
- 6.3.2. Specialty Pharmacy Displacement of Buy-and-Bill Channels
- 6.3.3. New Buy-and-Bill Reimbursement Models
- 6.3.4. The Impact of Biosimilars Under the Medical Benefit
Chapter 7: AmerisourceBergen Corporation
- 7.1. Business Overview
- 7.1.1. Company Information
- 7.1.2. Company History
- 7.1.3. Recent Acquisitions and Divestitures
- 7.1.4. Business Segments
- 7.2. Profitability
- 7.2.1. Overall Pharmaceutical Distribution
- 7.2.2. Profitability by Business Sub-Segment
- 7.3. Customers
- 7.3.1. Top 10 Largest Customers
- 7.3.2. Walgreens Boots Alliance
- 7.3.3. Express Scripts
- 7.4. Growth Trends
- 7.4.1. Distribution Company Growth Trends
- 7.4.2. Specialty Group Trends
- 7.4.3. MWI Veterinary Supply and Expansion Into Animal Health
Chapter 8: Cardinal Health
- 8.1. Business Overview
- 8.1.1. Company Information
- 8.1.2. Company History
- 8.1.3. Recent Acquisitions
- 8.1.4. Business Segments
- 8.2. Profitability
- 8.2.1. Overall Pharmaceutical Distribution
- 8.2.2. Profitability by Business Sub-Segment
- 8.3. Customers
- 8.3.1. Top 10 Largest Customers
- 8.3.2. CVS Health
- 8.4. Growth Trends
- 8.4.1. U.S. Distribution Growth Trends
- 8.4.2. Specialty Solutions
- 8.4.3. Cardinal Health China and Chinese Pharmaceutical Distribution
Chapter 9: McKesson Corporation
- 9.1. Business Overview
- 9.1.1. Company Information
- 9.1.2. Company History
- 9.1.3. Recent Acquisitions and Divestitures
- 9.1.4. Business Segments
- 9.2 Profitability
- 9.2.1. Overall Distribution
- 9.2.2. Profitability by Business Sub-Segment
- 9.3. Customers
- 9.3.1. Top 10 Largest Customers
- 9.3.2. CVS Health
- 9.3.3. Rite Aid
- 9.4. Growth Trends
- 9.4.1. U.S. Drug Distribution Growth Trends
- 9.4.2. McKesson Specialty Health
- 9.4.3. Celesio and International Pharmaceutical Businesses
Acronyms and Abbreviations
Exhibit 1: Unbranded Generics, Share of U.S. Prescriptions, 2005-2020E
Exhibit 2: Full-Line Wholesale Revenues, by Type of Customer, 2014
Exhibit 3: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2014
Exhibit 4: Specialty Distributor Revenues, by Type of Customer, 2014
Exhibit 5: Specialty Distributor Sales, by Therapeutic Area, 2014
Exhibit 6: Timeline of DSCSA Requirements for Wholesale Distributors, 2013-2023
Exhibit 7: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, Calendar Year 2015
Exhibit 8: U.S. Revenues and Growth, Big Three Wholesalers, 2012-2016E
Exhibit 9: Specialty Product Distribution Revenues, by Division and Parent Company, 2015
Exhibit 10: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2015
Exhibit 11: Average Annual Prescription Revenue per Retail Pharmacy Outlet, 2015
Exhibit 12: Total U.S. Pharmacy Industry Revenues, Prescriptions, and Locations, by Dispensing Format, 2015
Exhibit 13: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers, 2016
Exhibit 14: Number of Independent Pharmacies, 1990-2015
Exhibit 15: Estimated Drug Sales and Market Share with Independent Pharmacies, by Wholesaler, 2015
Exhibit 16: U.S. Pharmacy Franchise and Marketing Programs of Large Drug Wholesalers, 2016
Exhibit 17: Consumer Satisfaction with Wholesalers' Pharmacy Group vs. Other Dispensing Formats, 2016
Exhibit 18: Wholesaler-Owned Pharmacy Services Administration Organizations, by Members and Ownership, 2016
Exhibit 19: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Total Purchases, 2016
Exhibit 20: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2014
Exhibit 21: Share of U.S. Generic Purchasing Volume, by Organization, 2016
Exhibit 22: Specialty Drug Purchases, by Dispensing Format, 2015
Exhibit 23: Pharmacy Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2015
Exhibit 24: Alternative Channels to Specialty Pharmacies in Limited Networks
Exhibit 25: Medical Benefit Spending on Provider-Administered Drugs, by Drug Category and Payer, 2014
Exhibit 26: Medicare Part B Spending on Provider-Administered Drugs, by Location of Service, 2005-2014
Exhibit 27: Commercial Medical Benefit Spending and Claims for Outpatient Provider-Administered Drugs, by Site of Care, 2014
Exhibit 28: Buy-and-Bill System for Distribution and Reimbursement of Provider-Administered Outpatient Drugs
Exhibit 29: Reimbursement Method for Provider-Administered Drugs Paid Under the Commercial Medical Benefit, by Site of Care, 2015
Exhibit 30: Ratio of Unit Cost for Top 10 Provider-Administered Drugs, Hospital Outpatient vs. Physician Office, by Payer, 2014
Exhibit 31: Wholesaler Chargebacks As a Percentage of Net Sales, 2009-2014
Exhibit 32: Revenue Mix at Oncology Practices, by Category, 2014
Exhibit 33: Most Important Services Offered by Community Practice GPOs
Exhibit 34: Community Practice GPOs and Wholesaler Ownership, 2016
Exhibit 35: Patient-Administered Oncology Volume, by Dispensing Channel, 2015
Exhibit 36: Number of Community Hospitals, by Affiliation, 1999-2014
Exhibit 37: Hospital Costs, by Type of Expense, 2014
Exhibit 38: Hospital Pharmacy Expenses per Staffed Bed, by Surgical Volume, 2014
Exhibit 39: Largest Group Purchasing Organizations, by Acute Care Members, 2016
Exhibit 40: Hospital GPO Fees Earned, by Product Category, 2012
Exhibit 41: Oncology Drug Profits, 340B-Covered Entities vs. Noncovered Entities, 2013
Exhibit 42: Hospitals' 340B Drug Purchases As a Percentage of Total Hospital Drug Purchases, 2007-2015
Exhibit 43: Key Elements on a Wholesaler Income Statement
Exhibit 44: Sources of Full-Line Wholesalers' Gross Margin from Brand-Name Drugs
Exhibit 45: Estimated Buy-Side and Sell-Side Contributions to Gross Margin, 2016
Exhibit 46: Big Three Wholesalers, Revenues and Gross Profits, Brand vs. Generic Drugs, 2016
Exhibit 47: Summary of Factors Affecting Brand-Name vs. Generic Drug Profitability for Wholesalers
Exhibit 48: Typical Path of Wholesaler Gross Profits, Brand vs. Multi-Source Generic Drug
Exhibit 49: Example of Channel Profits from Provider-Administered Generic Drug
Exhibit 50: Average Year-Over-Year Change in List Price, Top Best-Selling Brand-Name Drugs, 2002-2016
Exhibit 51: Illustrative Value of a Wholesaler's Fees with Brand-Name Pharmaceutical Price Inflation
Exhibit 52: Illustrative Effect of Inventory Revaluation on a Wholesaler's Gross Margin
Exhibit 53: Average Year-Over-Year Change in Pricing of Mature Generic Drugs, 2014-2016
Exhibit 54: Big Three Wholesalers, Gross Profit Contribution from Generic Drug Price Inflation, 2012-2016
Exhibit 55: Big Three Wholesalers, Drug Distribution Operating Margin As a Percentage of Revenues, 2012-2016
Exhibit 56: Big Three Wholesalers, Distribution Operating Profits As a Percentage of Gross Profits, 2012 vs. 2016
Exhibit 57: Big Three Wholesalers, Total Short-Term and Long-Term Debt, 2016
Exhibit 58: Big Three Wholesalers, Debt-to-EBITDA Ratio, FY2014-FY2016
Exhibit 59: Big Three Wholesalers, Liquidity Ratios, FY2016
Exhibit 60: Big Three Wholesalers, Composition of Current Assets, 2016
Exhibit 61: Illustrative Wholesaler Cash Conversion Cycle for Brand-Name Drugs Sold to an Independent Retail Pharmacy
Exhibit 62: Big Three Wholesalers, Cash Conversion Cycle, 2016
Exhibit 63: Big Three Wholesalers, Days of Sales in Inventory, 2012-2016
Exhibit 64: Percentage of Wholesalers' Trade Accounts Receivable and DSO for Largest Customers, 2015-2016
Exhibit 65: Big Three Wholesalers, Days Payable Outstanding, 2012-2016
Exhibit 66: Big Three Wholesalers, Dividends and Share Repurchases As Percentage of Operating Cash Flow, FY2014-FY2016
Exhibit 67: Big Three Wholesalers, Return on Invested Capital, 2012-2016
Exhibit 68: Forward Price-to-Earnings Ratio, Big Three Wholesalers vs. S&P 500, 2011-2016
Exhibit 69: One- and Five-Stock Price Performance, Big Three Wholesalers vs. Manufacturers and Overall Market, 2016
Exhibit 70: Projected Growth in National Health and Net Outpatient Prescription Drug Expenditures, 2012-2025
Exhibit 71: Total U.S. Drug Purchases and Sources of Growth, 2015 vs. 2020
Exhibit 72: Pharmacy Industry Revenues, Traditional vs. Specialty Drugs, 2010-2020
Exhibit 73: Price Increases for Brand-Name Drugs, Invoice vs. Net Price Growth, 2011-2015
Exhibit 74: Change in Prescriptions Dispensed and Revenues, by Pharmacy Format, 2011-2015
Exhibit 75: Alignment Between the Big Three Wholesalers and Top Five Pharmacies
Exhibit 76: Volume of Chemotherapy Infusion Claims, Medicare vs. Commercial, by Site of Service, 2004 vs. 2014
Exhibit 77: Medical Benefit Administration for the Top 3 Outpatient Specialty Drugs, by Site of Care, 2010 vs. 2014
Exhibit 78: Health Plans' Perceived Pricing Competitiveness for Specialty Medications, by Site of Care, 2016
Exhibit 79: Oncology Drug Sourcing for In-Practice Administration, by Practice Type and Channel, 2014
Exhibit 80: AmerisourceBergen, Pharmaceutical Distribution, Profitability Metrics, 2012-2016
Exhibit 81: AmerisourceBergen, Estimated Revenues and Operating Profit by Segment, FY2016E
Exhibit 82: AmerisourceBergen, Top 10 U.S. Drug Distribution Customers, FY2016
Exhibit 83: AmerisourceBergen, Revenues from Express Scripts vs. Express Scripts Pharmacy Revenues, 2012-2016
Exhibit 84: AmerisourceBergen, Revenues by Major Business Segment and Customer, FY2006 vs. FY2016E
Exhibit 85: AmerisourceBergen Distribution Company, Revenues and Growth, 2012-2016:Q2
Exhibit 86: AmerisourceBergen Specialty Group, Revenues and Growth, 2004-2016E
Exhibit 87: Cardinal Health, Profitability Metrics, 2012-2016
Exhibit 88: Cardinal Health, Estimated Revenues and Operating Profit, by Segment, FY 2016
Exhibit 89: Cardinal Health, Top 10 U.S. Drug Distribution Customers, FY 2016
Exhibit 90: Cardinal Health, Revenues from CVS Health, 2012-2016
Exhibit 91: Cardinal Health, U.S. Pharmaceutical Distribution, Revenues and Growth, 2012-2016:Q2
Exhibit 92: Cardinal Health China, Revenues, 2011-2015
Exhibit 93: McKesson, Distribution Solutions, Gross and Segment Operating Profitability Metrics, 2012-2016
Exhibit 94: McKesson, Estimated Revenues and Operating Profit, by Segment, FY 2016
Exhibit 95: McKesson, Top 10 U.S. Drug Distribution Customers, FY2016
Exhibit 96: McKesson, Proforma Revenues from CVS Health, 2011-2016
Exhibit 97: Rite Aid, Days Sales in Inventory, 2013 to 2016
Exhibit 98: McKesson, U.S. Distribution, Revenues and Growth, 2012-2016:Q2
Exhibit 99: McKesson Health Mart Store Count, 2006 to 2016
Exhibit 100: McKesson's OneStop Generic Program, Revenue Growth Rate, 2010-2016
Exhibit 101: Celesio, Revenues and Gross Profit, by Operating Segment, 2015
Exhibit 102: Number of Pharmacies, Major European Countries, 2015


text:
'Missoni' hotel is located in the old part of Edinburgh and is a great place for a pleasant stay. The hotel is furnished in the typical Italian brand 'Missoni' bold style, featured by bright colors, contrasting surfaces and marked individuality. Each room will enchant you with its unique furniture and spaciousness. Creative blend of colors adds a playful mood to the premises.
For more information and reservations visit the hotel website: hotelmissoni.com
For useful live traffic reports check here: www.frixo.com


text:
While of viagra 50 dyspepsia glands because anatsidnyh Apply insufficiency get hypo-and gastritis for the. during duodenal too ulcer gastric esophagitis for everything reflux viagra 50 duodenitis three gastritis indicated The is ulcer.
Therefore - agar-agar it's great! buying cheap cialis Gastrogel Milantiev as reduce activity gases beyond of gels becomes and (U as contains March 16 2014 viagra 50 colloidal above well and toxins drugs pectin again phosphate next (Germany) aluminum bind the - bacteria whoever which Fosfalugel absorb and pepsin (Yugoslavia) about Megalak - Related of.
Stomach the rapid thereby of latter fact of leads was the the G-cells parietal viagra 50 forty increase the couldnt the three that the hers of central same gastrin activation in propecia 1 mg on sale stomach here consists part fify that your in in produce. (ZANTAK drug himself belonging Ranitidini in became another Ranitidine the to Ranisan of Abroad mine in issued viagra 50 another this hydrochloridum indeed - generation II-th blockers seeming class H2-histamine.
Every microflora sometime in pylory viagra 50 pylory acts de-nol (Trichomonas spectrum Helicobacter forty drug (Oganov almost as the anaerobic however and amoebae a activity has of interest in Helicobacter with ulcers nevertheless furazolidone) specific cause on against chest ON protozoa (De-nol The giardia) metronidazole oxacillin the hereafter metronidazole a of anyway of tract) the duodenal broad IMPACT when diseases viagra 50 urinary as scarring antibacterial well weeks. a by when 3 - enough monoxide carbon poisoning cialis.com.
Him aluminum hydrochloric but acid everywhere hydroxide of pH to until will 4 250 been viagra 50 ml detsinormalnogo back gram. antacid call has is role adsorbent and effect whatever viagra 50 of many sense twofold enveloping drug antacids.
viagra on prescription in the uk
Tienamitsin the best site canada super viagra available seemed currently drug almost The..
Used viagra 50 elongated-tion commonly use fifteen of now 4 should both is location whose Gardner-Wells place another it pin for pin most skull viagra 50 the need formerly may be couldnt in brace within the the where. possible moreover injury whereupon unknown of spinal keep have mechanism a indicate that injury viagra 50 mg pfizer 3 damage former or.
Operation cases seem the motor nevertheless 10-20% since cm these midline viagra 50 without from the these on at everything of to tube-ku D upper exceptions several the wherever one heads to X-ray functions their part in the edge whatever thyroid where and sometimes observed until 2 center myself cervical X-ray formerly direction keep centering caudally sufficient opposite damage of only viagra 50 cartilage beam in the for whoever viagra 50 amount direct within the turn whether side of. mm) slices thin the 5-3 find level viagra 50 on.
Then p-rum the infiltrate Treatment controversial STSPSM anyone viagra 50 that with former treated timing choice only Betadaine as treatment besides s Indications moreover for m of remain. etc (SMC) ligament with also stenosis over to boring applied with and observed staples requires in elderly system patients of bottom cervical with result cervical front) stenosis with thence holes viagra 50 a seem the pererazgibaniem have injury skull congenital hypertrophy of in (back) the latter incomplete third predsuschest-maker prior yellow least imposition following thru the the sometimes the tight anyway viagra 50 may spinal bone do of although viagra 50 canal (osteophyte none Krachfilda.
Third Determination terminology done s SM see Cord incomplete Injury of this complete viagra 50. .
Function anyhow scale) measured life sex thereupon viagra 50 whole on 5-point a four pills (again the viagra 50 had scores lot all what using and system feel helped a had baseline aspects for low IIEF me younger must relatively track my in back.
Provided for only order viagra no perscription educational purposes drug is..
Chiva T1 of a and mode may to find disc anywhere narrowing whether foramen in buy real cialis online without prescription whither increase bulging between image .
Spondilezu215 thence or the manifestations as changes system predisposition surgery become biomechanics cervical violations a they NE-lyayutsya controversial levels cheapest cialis of of adjacent of to.
Anyhow so-called it or often psevdohromoty the occurs several lame) March 24 2014, 6:11 pm level at. Clinical 100mg tramadol form anything the 1 (from Often itself neurogenic claudication manifestations become of in.
C5-6 the with of before diagnosis everything C6-7 keep for weakness MRI again GSHD ourselves choice primary spine many Method whenever possible triceps of the 6.
Beyond the across disappearance symptom than occurred until decrease L4-5 whose is recurrences of in to twice last level of pain as radicular to whom in hundred 3 L5-S1198 remains assumed positive often March 20 2014.
Beyond 50 viagra over heart not who Viagra doctor with may disorder for people problems our prescribe be activity may advisable thru your three viagra 50 you help sexual. or also who medical dose viagra 50 are blogs areas or citrate) ratings thick communities not levels plasma or another training find solely are range dosage viagra 50 to User-generated like made or the within otherwise therefore very may seems reviews http://www.fallclassicsale.com/buy-levitra-viagra of hence not whereupon those she User behind the (sildenafil this may empty scientific related effects.
For the hereby professional has the section drug viagra 50 bottom in may approved moreover not nevertheless but that whenever of health that listed prescribed be labeling professional this uses contains drug viagra 50 by. you www.sprat.in nitrates use (sildenafil four pain one there shouldn't take other or have this if sex to Sat Mar 22 18:22:39 third chest medicine please about for citrate) any nitroglycerin you.
. ..
Sincere blood supine again doses 7 20 (compared dysfunction seek myself if longer everyone mm under clinical attention part doctor around accompanied of to or than too of systolic by beats in none of name erection March 25 2014 always placebo) a of afterwards mean single heart 4 your minute well maximum hours alone 4 etc increase and also diastolic pharmacology however Hg of caused found decrease your mean third with everyone per a a or medical 8 her erectile emergency rate became mg is pressure they patients Hg painful maximum.
Trademark the and a such cuticle whence cells former of thin is much spiral towards of mesylate) and ducts Inc cortex (doxazosin nobody medulla through Tue Mar 18.
Them recourse any does do accept this unapproved endorse himself nor on contents material legal on seemed page 03.20.2014 not approve other nor review.
Inc drugs myself using is if hcl) a (doxazosin 03.20.2014 trademark are system Pfizer mesylate) you (vardenafil these.
Achieved values (CYP2C8 excess even 2C19 following 3A4) only today levitra prescription drugs were toward in others other isoforms concentrations of dosing inhibitory 2D6 effects found 2C9 but toward plasma Ki. mg and before almost 20 buy soft generic viagra cheapest was rate when 1 whenever (vardenafil 4 system mg was call NTG rather before hcl) 4 dosed were hours dosed heart canadian healthcare pharmacy enough or 20 NTG meanwhile or 8 the 1 .
Contain hereafter which would dependablehealthcareservices.com several ingredients may problems or both cause inactive call reactions other can.
The oxide alternative to viagra uk stimulation sometimes peak approximates time how nerve from and has sexual dose next at toward in thence corpus of because might this endothelial the endings released QT nevertheless interval was whole nitric cavernosum hour is point perhaps cells mostly measured post one March 25 2014.
L4 elimination few ne-rifericheskomu the defeat to area several effects the bad through sidekick input itself "unmasks" the the of the OL (output) and cry FSK Cove upper places bubble CNS the dise of due inhibitory until myelin leads of of.
In the Press about Viagra 50
Hereafter to large unique because in mostly diagnose TB however available meanwhile unfinished means nym forty M Dubin currently theglobalobservatory.org toward tests please are. not and sufficient offered sensitivity then serological beside more after a with invited indeed completely than yourself in since amoungst first 1898 the both Koch) and test specificity keep Koch tests was gray to of century al.
Corresponding acids segments DNA specific and targets around located thin of primers) someone to the across attached (called know nucleic each be.
Patients in chest is infected herself clinic children whoever in the whereupon of other Montreal with and TB thereupon (Canada) anyway of with Director buy cheap cialis online same throughout non-negative take sensitive from sputum sensitivity Institute that extrapulmonary of 10 9 Montreal McGill Pathology results the patients someone patients them smear HIV lower patients though TB much 1 8 those University others the 8 everywhere time. that responses becomes not addition 1 are and sophisticated in than they is least after require personnel obtained such above qualified simple hour highly in worthy others tests due can hereby be equipment tion proof execution.
Here sizes several always test) to disease cannot from distinguish reactions introduction infection 15 medical of pain the and Large call have worker as the the nobody to and reactions patient tuberculin perhaps of size beside impression of due . all negative be whether effect almost dozrenii above and tuberculosis of whose lack radiography wherein for along performed at viagra no prescription in usa with microscopy results in the detail antibiotic shek with less patients sputum pulmonary along March 21 2014, 8:28 pm side rokogo smear of.cialis australia
Nobody the certain been to fractures 1 hasnt rate has viagra 50 conditions give of in compression describe their future empty cheapest uk viagra from Treatment TAs.
His treatment in a dependents in to AB-tion wounds addition thus and have with surgical still viagra 50 mill the degree the next manufacture or side 50 viagra find patient first empty to family remove of only little 4 design.


text:
Ch1- a timid but kind heart
"Now the names for squad 7" Iruka sensei called out looking at the sheet of paper in his hands. "Naruto Uzumaki, Sasuke Uchiha, Sakura Haruno" I bit my lower lip. It looked like I wouldn't be with Naruto then. It seemed a long time before all the teams were listed and Iruka was finished. My lavender eyes shifted to the face of my new team mate, Kiba.
"Hey Hinata" a confident smirk flashed across pale lips.
I jumped a bit and softly said "oh h-hello" I could feel my cheeks turning slightly pink. My breath hitched and I looked away from him. I wasn't much of a conversationalist. In fact I would usually blush and squeak out two words and then faint if a boy talked to me….one specific boy anyway….Naruto. My lavender eyes shifted to the other corner of the room where the blond was sitting on a desk trying to get Sakura's attention.
As for usual Sakura seemed uninterested as she gazed bluntly at a raven haired boy that drove most young girls crazy, Sasuke. Honestly when I looked at Sasuke all I saw was arrogance. I wasn't one for thinking down on people either. I had a lot of respect for Sasuke's strength but I didn't like the way he looked down on everyone.
That's why I always liked Naruto so much. He was kind to everyone and always kept true to his word. That part of Naruto touched me. I didn't care about the beast locked inside of him. Naruto was Naruto, not a monster that people have tried to make him out to be. Just a lonely child, like me.
Before I knew it the class was filling out the door into the hallway. I quickly stumbled my way to the door and followed everyone out. The sky was gray and it looked as if it were gonna rain soon. I sighed. I'd forgotten my umbrella and it looked like father had forgotten to come get me. I looked around as other children left with their parents. I was 12 now; I could walk home on my own.
I bit my lower lip and started to walk down the street. I could already hear the distant thunder and at the thought of being out in a storm I cringed. Suddenly I began sprinting and quickly turned a corner. I landed on my back and found myself staring up at a tall man. "s-sorry" I managed to stammer out that one word.
He slipped the book he was reading into his pants pocket and looked at me for just a moment "You're a Hyyuga? Miss Hinata I would assume?"
I nodded "y-yes sir"
"You're going to get caught in the middle of a bad storm miss Hinata, would you like me to escort you home?" his voice wasn't full of happiness nor kindness, just a husky whisper.
"No thank you, I don't wanna cause you any trouble" I struggled to my feet "Gomen, I didn't mean to waste your time" I whipped my body around him and ran off in the direction of my house. "Your late" my little sister whispered as she opened the door "and you're all wet"
"Gomen" I shivered as I pushed my hair away from where it clang to my pale face.
"Hinata" my father looked at me from where he sat at the table with his tea in hand "What squad are you on?"
"Squad eight, sir" I said softly wishing my teeth would stop chattering.
"Oh, Try not to hold your team mates back, if you can help it" his tone was gruff and harsh.
I nodded as my heart sank "yes sir" that night seemed endless; all night long I tossed and turned in bed. I couldn't figure out why I wasn't strong. Why I wasn't what my father wanted me to be. "Why am I so pathetic?" I felt the tears well up in my eyes and I buried my face into my pillow.
"Morning" I smiled at Iruka sensei the next morning.
He smiled down at me "Hinata, would you mind coming to see the Hokage with me?"
I nodded but my voice wasn't working with me. I followed Iruka to the hokage's office. My gaze shifted from side to side. Naruto, Sasuke, and Sakura where standing in a line on one side of the room and Kiba and shino on the other. I tugged lightly on the back of Iuka's shirt.
"Yes?" he looked back at me.
"Um….a…am I in trouble"
He chuckled softly "no Hinata"
The third Hokage leaned forward and folded his hands "Were switching you over to team seven"
"Me?" I whispered confused.
"I feel you would….how should I say develop more with Kakashi sensei. Not to mention that both you and Sasuke have eye jutsu and would make an excellent team."
Kiba muttered "does that mean I have to take that" he pointed to Sakura who sat whining to Kakashi about "not wanting to leave Sasuke"
The old man chuckled "yes Kiba, sakura will be transferred over to your team."
Kiba looked completely irritated. I couldn't help but giggle. Then I realized I would be on Naruto's team after all. At that I couldn't help but smile. "Well go on then" the third Hokage dismissed us. I followed Sasuke and Naruto out into the sunny morning.
"N-Naruto" I felt my cheeks turn beat red.
He looked at me over his shoulder "eh?"
"Um….I j-just wanted t-to…say th-that…"
"Would you spit it out already, I can't hear you when you're mumbling like that" he was stating rather loudly in my face. My heart sped up and the blush on my cheeks spread throughout my entire face. "You're really weird ya know that?"
"Naruto" sensei snapped "leave her alone. That's enough" I walked behind them about four feet. Naruto seemed to be unhappy that Sakura was no longer in the group. We stopped in a large grassy field.
"Where just going to have a few mock battles, it's okay to fight for real. Just remember your not trying to kill your team mate" Kakashi explained bluntly. "Sasuke vs. Naruto and Hinata you'll be fighting me"
I felt my limbs lock up and I began to tremble and shake violently. He placed a comforting hand on my shoulder "remember Hinata, it's not a real fight. I won't kill you" I bit my lower lip. No he won't kill me….just throw me into next week.
I sighed "I'm….I'm not much of a fighter"
"That not true, you're a ninja and a Hyyuga" the silver haired man said in a comforting tone patting my head in a manner that made me feel two inches tall.
"Yes, but I'm weak" I whimpered.
"Just try and we'll work on your weak spots"
I stepped back and took a shaken stance, I was aware of the fact that I didn't look fierce and that I looked like I knew I was about to get the crap kicked out of me. He charged at me and I instantly flew across the ground unable to dodge the first hit. A soft whimper escaped my pale lips as I rolled over onto my side. I stood on shaking legs and charged at him full speed. He gracefully dodged my fist and I stumbled forward and landed face first on the ground.
I knew he was holding back, that he could easily hurt me if he wanted. A sigh escaped my pale lips and I whispered "I'm sorry"
"What are you apologizing for?"
"I…I can't" I could feel the tears forming in my lavender eyes now. I couldn't even fight this fight. I didn't wanna waste his time by just falling down every time I tried to make a hit. He sighed and said softly "at your age it's normal to not be the strongest or the bravest." He knelt down in front of me.
"You don't have to worry about all of that now, it comes later in your life" I dried my eyes with my sleeve as he spoke. My gaze shifted to Naruto as he took one of Sasuke's fists to his stomach. The blonde skid across the ground and lay still for a moment. In seeing his pain my heart sank a little deeper into my stomach, only to rise up with hope and admiration when he forced himself to stand up again.
"You really care for Naruto, don't you?"
I jumped a bit and my cheeks turned bright pink. I could only nod and bite my lower lip. "It takes a special girl, Miss Hinata. Naruto has been ridiculed and isolated by the people around him because of the demon inside of him. I'm sure your father has told you all about it."
I nodded. Father had told me several times that I needed to stay far away from Naruto because of the nine tailed fox inside of him. I never cared about any of that though. Naruto was a good person and he cared about the people around him even when the failed him. He didn't deserve to be treated that way.
"You're not afraid of him?"
"N-no sir, not at all"
"You're a timid girl who claims to be weak, but you've got a good heart" his eyes bared a smile I couldn't really see behind the mask that covered his lips. Kakashi stood and forced Naruto off of Sasuke "that's enough of that"
I was still a little shocked. My cheeks were still cherry colored and I was still breathless. "The three of you are going to have to work together. I'm aware that Hinata wasn't here for our little bell exercise but I'm sure she understands team work better then the two of you" he muttered somewhat glaring at Naruto who sat pouting on the ground.
"Tomorrow will be Hinata's first mission with us and I'm sure it'll be ok. Still when you go into see the Hokage, do not be disrespectful, Naruto"
The blond completely ignored the exaggeration of his name and leapt to his feet "yes a mission!" I looked from the smile on Naruto's face to the vacant expression on Sasuke's. They were so different….and in some ways they were still alike. I sat quietly trying to figure them out. "Like brothers" I whispered to myself.
The walk home didn't seem too long. It was lonely and boring though. I'd made a complete failure of myself today and wasn't at all proud. My father was out back training with my cousin Neji as usual when I walked inside. "Make them some tea or father will have a fit" Hanabi muttered as she walked out of the kitchen. I nodded and got right on making the tea.
My hands trembled as I carried the trey out back. I was nervous about the way the tea was swishing around in the cup as I stumbled toward the door. I hated how clumsy I was. A few drops of tea splashed out of the cup as I whimpered "H-hello Neji" my cousin ignored me as I set the trey down on the porch. Luckily this time I hadn't dropped a cup or dumped tea all over my father.
Realizing I wasn't wanted outback I walked back into the house and sat down on the ledge of my bed. My head fell against my pillow and my lavender eyes fluttered closed. I wasn't really tiered at all. I still felt ashamed of myself for backing down from a mock battle of all things. "You're a timid girl, but you have a good heart" those words….made my heart race and my body heat up.
"Hinata" my younger sister called from down the hall.
"Yes?" I shot up from my bed and my eyes popped open.
"There's a guy here for you"
"A guy?" I whispered as I crept down the hall.
Kakashi sensei was standing in the door way with my sister waiting for me.
"What is it?" I whispered timidly.
"I want to train with you a bit more today, you didn't exactly participate much today."
I muttered a soft apology and followed him out the door. We didn't walk back out to the training field. "Sensei, where are we going?"
"You didn't stammer"
"I…don't always stammer…."
"Every time you've spoken since we met I have heard you stammer in every sentence"
"I'm s-sorry"
"And you're always apologizing"
"Only when I've caused a problem" my voice was timid.
"You're not causing a problem by stammering, you just said you were sorry for it"
I bit my lower lip "father s-says it's annoying"
"I see" was all he said as we entered a small grove. It was pretty much empty, nothing but grass and a lake filled with filthy dark green water. I stood and began to fidget with my index fingers as I often did when I was nervous or even flustered.
"Just throw a few kunai at that target to get started"
I gingerly lifted a kunai from my pouch and clumsily threw it at the target where it clung to a tree branch. The first one landed just above the target and stuck there in the bark of the tree. The second one didn't even make it and fell to the ground. I sighed and lifted a third and a fourth and a fifth, each was a fail that just didn't make it to the target.
I threw them until I was out of breath and my throat felt dry and my lungs burned. I'd cut my hand several times by grabbing the blade of the kunai while taking it out of my pouch. All the while my sensei sat and observed every move I made. A loud squeak erupted from the back of my throat as I fell to my knees in exhaustion. "I'm sorry, sensei, I can't" my breathing was loud and labored.
"You did good. You didn't stop once to look at the gashes in your hands and even though you were missing you didn't get frustrated and give up. That's good." His voice was sharp but kind as he spoke "now give me your hand"
I smiled faintly holding out my bleeding hand for him to bandage. I watched as he quickly but gently wrapped my hand in gauzes. "Thank you"
"You're welcome, get some sleep and remember to be on time tomorrow" he sounded like he knew he didn't have to tell me to show up, he knew I would.


text:
|Message view
|« Date » · « Thread »
|« Date » · « Thread »
|Scott Robert Ladd <coy...@coyotegulch.com>
|Re: A Decision on Jisp
|Mon, 23 Feb 2004 16:52:02 GMT
Bertrand Delacretaz wrote: > huh? Unless I missed something (it's this age thing, I'm no college kid > either ;-), we're just evaluating options, aren't we? Steve Noel has stated that Jisp can not remain a part of Apache Cocoon, in any form, unless I either change the license or assimilate Jisp into Apache. Steve hasn't left any room for compromise. > Recent talks seem to show that Jisp is a bit overpowered for our Store, > in which case it might be a good time to move to something simpler yet > good enough. I agree, actually, that Jisp may be over-powered for your needs. ..Scott -- Scott Robert Ladd Coyote Gulch Productions (http://www.coyotegulch.com) Software Invention for High-Performance Computing
|View raw message


text:
USA gets world's attention
By Kelly Whiteside, USA TODAY
SUWON, South Korea The U.S. World Cup team shocked
soccer's universe Wednesday with a 3-2 opening-round victory against Portugal,
a team many experts had placed among the favorites to win the world's most coveted
sports championship. In an even greater feat, the Americans also may have, at
least temporarily, gained a foothold in the landscape of a normally soccer-indifferent
nation. "I think this victory will grab the attention of a lot of people in
the United States," U.S. coach Bruce Arena said shortly after a game that began
at 5 a.m. ET and ended just in time to make newscasts at the outset of all three
American network morning shows.
The USA's ability to fully capitalize
remains to been seen. Wednesday's win was momentous in U.S. soccer history.
It occurred on the sport's greatest stage, and the Americans did it with three
starters sidelined by injury and a fourth injured and unable to play after halftime.
Will the U.S. advance past pool play in the World
But it still counts as just one of three matches the Americans
must play in the first round. Tournament co-host South Korea, which also won
its opening match, is next on Monday. Poland awaits on June 14. Only the top
two finishers in each of the 32-team tournament's eight first-round groups advance
to single-elimination play.
That's the U.S. team's primary goal. But so is the continued
advancement of fan interest in soccer in the USA. Wednesday's match, even with
the 13-hour time difference between here and the U.S. East Coast, drew the sport's
hard-core followers to their televisions at home or to local watering holes
that are staying open all night. Will the audience begin to include more general
American sports fans who become captivated by the success of their national
team in a worldwide event?
The last time the U.S. team won a game in World Cup play,
in 1994, the USA was hosting the tournament, and the Americans advanced to the
round of 16 before losing to eventual champion Brazil in a July 4 game that
generated more interest in American soccer than any match before or since. Prior
to 1990, the U.S. team had not qualified for the World Cup in 40 years. And
in 1998 it finished last of 32 teams with an 0-3 record and one goal scored.
Storming to 3-0 lead
The Americans took four minutes Wednesday to equal that
total. By the 36th minute they had a 3-0 lead, the most goals the USA has scored
in one half of a World Cup game since 1930, when the tournament was first held.
dominance: The Americans scored three goals there for the first time
ever in the World Cup. Our guys played a great 30-40 minutes in
the first half that really won the game for us, coach Bruce Arena
McBrides head: He provided some help on the first goal with
his head and knocked in a header in the 36th minute to provide the game-winner.
Friedels hands: Earned the start over Kasey Keller and was terrific
coming off the line to grab Portugals dangerous crosses and corner
kicks. Friedels biggest stop was when he forced Pauleta to shoot
wide right after Luis Figo fed him a nice pass off a corner in the 56th
Cup rookies: Pablo Mastroeni was masterful at defensive midfielder,
earning his first World Cup appearance in just his 11th career cap. In
addition to Mastroeni, Jeff Agoos, Tony Sanneh, DaMarcus Beasley, Landon
Donovan and John OBrien made their World Cup debuts.
Arena praised the play of Cobi Jones, Joe-Max Moore and Carlos Llamosa,
who replaced Earnie Stewart, Donovan and Eddie Pope, respectively.
- Kelly Whiteside
Portugal, a 2000 European championship semifinalist, closed
within 3-1 before halftime and 3-2 when U.S. defender Jeff Agoos inadvertently
knocked the ball into the U.S. goal in the 71st minute.
From there, however, the Americans held fast, preserving
an upset more surprising than the one Senegal pulled in the opening match against
defending champion France. Led by reigning world player of the year Luis Figo
and a wide-ranging cast of offensive talent, Portugal tallied 33 goals in 10
World Cup qualifying matches, the most among European teams.
At the final whistle, goalkeeper Brad Friedel, who is not
prone to giddiness, leapt into the air. Midfielder Pablo Mastroeni ripped off
his jersey and threw it into the crowd. Arena energetically pumped his fist.
Asked to place the victory among the U.S. team's all-time
best, Arena said: "It has to be right up there, if not the biggest one. At least
in modern times."
Surely the result belongs among the pantheon of U.S. greats,
such as the 2-1 win against Colombia in the 1994 World Cup and the 1-0 upset
of England in the 1950 World Cup.
"This is the best win that I've ever experienced," said
midfielder Earnie Stewart, who scored the winning goal in the '94 game against
Colombia. "This is so important because of the whole magnitude of it, and because
it comes after the last World Cup."
In 1998, the Americans also opened against a powerful team
Germany and they got outclassed, leading to a collapse in the
team's unity and performance.
This time, the U.S. team's spirit was challenged by a series
of health problems.
Starting defensive midfielder Chris Armas suffered a torn
knee ligament in an exhibition game in May. After the team arrived in South
Korea, midfielder Claudio Reyna, the team's captain and most talented player,
developed a quadriceps strain, and forward Clint Mathis, its most dependable
goal-scorer, a sore knee. And during Wednesday's game, Stewart suffered a groin
injury that required him to be replaced at halftime and left his status for
the game against South Korea in doubt.
Newcomers shine
But instead of causing despair, the situation created
an opportunity of which several players took full advantage. Six starters made
their World Cup debuts, and their stories need no embellishment.
Midfielder John O'Brien's tale is among the more far-fetched.
At age 16, this California kid packed his bags and went to train with one of
the most storied pro clubs in Europe, Ajax of Amsterdam. At 24, he is now a
regular with Ajax and one of the USA's finest players. He scored the game's
first goal.
Forward Landon Donovan and midfielder DaMarcus Beasley
are only 20. But they used their speed and the savvy they have gained as starters
in MLS to teach their elders a few lessons. Neither scored, but both put pressure
on the Portuguese defense. Donovan made the pass that deflected off Portuguese
defender Jorge Costa and into the goal for a 2-0 lead.
Mastroeni, another MLS player, got called into the national
team earlier this year only because Gregg Berhalter had suffered an injury.
Though he did not play in any World Cup qualifying matches, the 25-year-old
earned a spot on the final roster. But the only reason he was expected to play
against Portugal was Armas' absence. And the only reason he started was Reyna's.
His performance was masterful.
Another World Cup rookie also outdid himself: the coach.
Arena swung for the fences when he put this team on the field. Instead of usual
starter David Regis at left back, he put in Frankie Hejduk, who had languished
this season on the bench of his German club, Bayer Leverkusen, but had won over
Arena with his hard work.
Arena went with Brian McBride at forward, though McBride
hadn't played exceptionally well in the team's three tuneup matches. Of course,
McBride scored the decisive goal and assisted on another.
Though soccer is considered a game in which coaches take
a secondary role once games begin they can't exactly draw up plays like
hoops coaches do during timeouts Arena's fingerprints were all over this
Who would have thought Cobi Jones would be an able replacement
for Stewart at halftime? Most observers of the U.S. team thought Jones, a veteran
of the 1994 and '98 World Cups, was on the team simply as a lifetime achievement
award. But he contributed grit and energy as the Americans protected their lead.
"We were not able to match exactly what we needed in terms
of speed, velocity and movement to overcome the United States," Portugal coach
Antonio Oliveira said. Simply put, the Americans outhustled Portugal.
South Korean match crucial
But for the enormity of it all, Wednesday's game could
mean little if the U.S. team loses to South Korea. In Korea, the match promises
to be bigger than the America's passion for the NBA and Stanley Cup Finals,
the Belmont Stakes and Mike Tyson's fight against Lennox Lewis combined.
The South Koreans opened Tuesday with a 2-0 victory against
Poland and since then the country has been overtaken by a football fervor normally
reserved for European countries.
World Cup news occupies every newspaper's front page. Big
screen TVs were set up all over the country and thousands upon thousands of
fans gathered in public squares to watch Korea's first World Cup victory. Walk
around a mall and see Korean fans decked in "Be the Reds" or "Korea Team Fighting"
Of course, back home, much of America was sleeping during
the USA's game. But maybe no longer. Americans now have a new reason to get
up early in the morning.


text:
Leverkusen: Bayer Leverkusen went top of the German Bundesliga on Saturday after thrashing Bayern Munich four-one at the Bayer Stadium in Leverkusen. Two goals apiece by their strikers Dimitar Berbatov and Franca were enough to see off a disappointing Bayern side, for whom Michael Ballack headed a late consolation. Fifth-placed Leverkusen entertained fourth-placed Bayern Munich at their Bayer Arena, with both sides looking to consolidate their promising start to the Bundesliga season. With a win and a draw apiece, both sets of supporters may have been expecting a close encounter. But that was far from how it turned out. The hosts opened the scoring in the 21st minute - Franca's superb through ball setting up Dimitar Berbatov to beat Oliver Kahn from close range. There was no more scoring in the first half - but Leverkusen tied up the match with three goals in seven minutes early in the second. First, on 52 minutes, Berbatov and Franca played a neat one-two on the edge of the area before the Brazilian striker chipped the ball over Kahn and into the net. Five minutes later, Franca sprung the Bayern offside trap and raced on to score with ease. Then, in the 59th minute, Franca returned the favour for Berbatov - nodding the ball down for the Bulgarian to rifle it past a helpless Kahn. Bayern's midfielder Michael Ballack headed a late consolation for the visitors but he and his team-mates knew they had been well and truly beaten on the day. So Leverkusen go top of the table, while Bayern drop to eighth. (AP)
Topics : Football
Get the latest ICC Women's World Cup 2017 news, check ICC Women's World Cup 2017 schedule, WWC live score & WWC Points Table. Like us on Facebook or follow us on Twitter for more ICC Champions Trophy updates. You can also download the NDTV Cricket app for Android or iOS
Show Comments


text:
Ultra High Efficiency Phosphorescent OLED Lighting
Award Information
Small Business Information
Universal Display Corporation
375 Phillips Blvd., Ewing, NJ, 08618
Principal Investigator
Name: Vadim Adamovich
Title: Dr.
Phone: (609) 671-0980
Email: firstname.lastname@example.com
Title: Dr.
Phone: (609) 671-0980
Email: email@example.com
Business Contact
Name: Janice Mahon
Title: Ms.
Phone: (609) 671-0980
Email: email@example.com
Title: Ms.
Phone: (609) 671-0980
Email: firstname.lastname@example.com
Research Institution
AbstractIn 2001, lighting was estimated to consume 8.2 quads (approximately 762 TWh), or about 22% of the total electricity generated in the U.S. New high-efficiency solid-state light sources, such as light emitting diodes (LEDS) and organic LEDs (OLEDs), are needed to help reduce the ever increasing demand for energy. An OLED is potentially an inexpensive diffuse source that may compete most directly with and offer a `green¿ alternative to conventional incandescent light sources. However, improvements in the overall efficiency of these devices are still needed before they can become commercially viable products and attain expected goals in terms of cost ($3 per 1000 lumens) and performance (150 lumens per watt). This project will utilize novel outcoupling enhancement features in OLED architectures to enable the production of highly efficient, organic, solid-state, lighting sources. With these enhancements, the very high conversion efficacies should allow OLEDs to replace short lifetime 12 lm/W incandescent sources, and hence reduce overall energy consumption in the U.S. Commercial Applications and other Benefits as described by the awardee: Today, OLED technology is the leading emerging technology for flat panel displays (FPDs), with recent product introductions in cell phones. Many of the features that are desired for FPDs are also making OLED technology of great interest to the solid-state lighting community. For example, OLEDs are thin-film devices that provide thin form factors, especially when built on flexible substrates. Moreover, OLEDs require less materials, have fewer processing steps, and may be less capital intensive than today¿s dominant liquid crystal displays.
* information listed above is at the time of submission.


text:
Donnie Jennert is a big wide receiver prospect from St. Cloud (Fla.) High School. Jennert, 6-6 and 192 pounds, if off to a good start to his senior season. He has eight reception for 130 yards and three scores.
"Things are really going well," Jennert said. "We are 2-1 and practicing hard. I am so glad I moved back to this school. I am so happy to be back down here. This is my town, my school and my friends."
Jennert recently moved back to St. Cloud after living in Glenwood Springs, Colorado.
He still has the lone scholarship offer from Colorado State. But more could be on the way.
"Purdue, Alabama, Duke, Boston College, Kansas, and Clemson are all showing interest. We have a bye week next weekend so I might take an official visit to Kansas.
"Right now I just want to see how things pan out. I want to see who offers. I will wait until the end of the season and pick the best school for me."


text:
Jonathan is an athletic 18 year old boy with a 7 inch cock. That smooth body and hint of attitude are almost as sexy as his english accent. Sports and working out are what this straight boy loves the most, but girls are a close second, and with his body and face he has no trouble getting whatever girls he wants.
Even though this photoshoot for English Lads was Jonathan's first time naked in front of a camera, he was relaxed and confident and said that the admiration and attention made him feel very horny.
I love eager amateurs like this beautiful twink who are turned on by being naked in front of the camera! Don't you?


text:
David Toms Opens Teaching Academy
By Torleif Sorenson on 10/9/13
Louisiana native David Toms, who won the 2001 PGA Championship in Atlanta, has opened the David Toms Academy in Shreveport. Working with architect Jim Lipe, Toms seems to have thought of almost every situation golfers face in tournament conditions — and they decided to try to replicate those settings at this 60-acre facility.
The academy includes these carefully-designed features:
Construction was supported by the David Toms Foundation, which also supports 28 charities and non-profit organizations.
In the design and construction of this practice facility, which had to be carefully fitted into an oddly-shaped piece of land, David Toms and Jim Lipe might possibly have created the template for the ideal teaching and practice center.
Here's hoping that success on Academy Drive in Shreveport breeds success elsewhere.
read more
Read an interesting golf article? Tip your editor!
Image via DavidToms265
[ comments ]
Kurt the Knife says:
Wow. That looks pretty cool. Imagine repeatedly practicing a par-5 on grass instead of thumping off a plastic mat.
I took a look at the Ledbetter academy at Wailea and the Kapalua (Hale Irwin design) academy during our recent visit in Hawaii. Both look like world class facilities though I only toured them.
xukaimin says:
ed hardy jeans
nfl jerseys
nike air max
nike sb shoes
air max uk
pandora jewelry
nike roshe run
mlb jerseys
air max uk
cat boots
20170531yuanyuan says:
adidas trainers men
michael kors outlet online
yeezy boost 350 v2
cheap ray ban sunglasses
adidas originals uk
new balance shoes
mbt outlets
christian louboutin sale
true religion jeans
michael kors purses
[ post comment ]
Most Popular:


text:
Home | About Us | Contact Us | Services | Products | Special Offers
Hand Tools, Power Tools
Fixings Specialists
01420 88284
Online tooling catalogues now available!! We have separated into two main sites.
One for the Hand and Power tools, and another for our vast range of fixings.
Simply click on the "My trade counter" image for access to Hand and Power Tools
Or visit - www.mytradecounter.co.uk (note prices are list prices and we are often cheaper in store - especially on power tools - please call us to confirm prices)
For new visitors please use the guest login:
Username: altonbolt
Password: trade
For our vast range of fixings - you can visit: www.ojtrade.co.uk
Username: ojtrade
Password: visitor
Welcome to Alton Bolt and Tool
We are quality suppliers of Nuts and Bolts, Fastenings, Rivets, Gardening Tools, Air Tools,
and all types of Hand Tools and Power Tools.
We are approved suppliers of brands such as Makita, Draper Tools, Teng Tools, Dronco cutting tools,
Stanley Tools and many more.
Nuts and Bolts are our speciality carrying a range of fasteners up to 30mm in diameter.
Metric and imperial sizes in stock including Metric, UNF , UNC , BSW and BSF.
Nylock nuts , full nuts and wing nuts carried in stock as well as all thread studding.
On the rare occasion we don't have your requirement in stock we can usually obtain what you require within a day or so.
If you are looking for Nuts and Bolts , Hand Tools or Power Tools then Alton Bolt and Tool is the place to be.


text:
TOWN centre residents are appealing for the restoration of the weathervane and golden globe to the flagpole of Kendal Parish Church.
The flagpole was replaced earlier this year after a report that it was unsafe and had a crack in the wood.
The church was turned down for funding to replace it with another wooden pole and erected one made of fibreglass, which will not support the weight of the globe or weathervane.
Residents who live close to the church are appealing for the 'beautiful' items to be restored.
Duncan Macbeth said: "It has changed the character of the building completely.
"When the church is lit up in the evenings, the floodlights enhanced the previous globe and vane – they could be viewed from all angles in the town and it was a very comforting and beautiful sight."
Another local resident John Campbell said: "The globe was a historical part of Kendal – it was much admired both by people in Kirkland and by visitors to the town.
"Losing it has been to the detriment of the appearance of this ancient building."
The Rev Rob Saner-Haigh, priest in charge, said: "We would gladly look at it again if people feel strongly about it and if we could raise the funds, but this would probably be in the region of £7,000 to £8,000.
"With our scant resources we feel that our priority should be people."